Skip to main content
Caplight Logo









PolyActiva

PolyActiva

Private
MelbourneHealthcare & Life Scienceshttps://polyactiva.com/

Last Round

Series C

May 30, 2025

Total Funding Raised

$46.39M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

PolyActiva is a biopharmaceutical company developing a biodegradable, sustained-release drug delivery platform for ophthalmic conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

ocular implantdrug deliverysustained-releasebiodegradable implantglaucoma treatmenteye drop alternativeophthalmologypolymeric prodrugintravitreal implantocular hypertensionbiopharmaceuticaldrug-polymer conjugatemedtechclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PolyActiva Comparables

Compare PolyActiva with similar companies based on industry and business-model similarity.

PolyActiva comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ripple Therapeutics
83%
Mati Therapeutics
78%
Ocular Therapeutix Inc
78%

PolyActiva Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 30, 2025
GrantMay 7, 2024
VC RoundAug 30, 2018
Series BFeb 19, 2013
Series BFeb 19, 2013
Series A
Jan 1, 2011

Key People

Founding team and executive leadership

Wes Brazell

Chief Financial Officer

Executive Team

PolyActiva Investors

Notable investors and investment history

PolyActiva investors
InvestorRounds
CUREatorGrant
Yuuwa CapitalVC Round, Series B
National Reconstruction Fund CorporationSeries C
Brandon CapitalSeries C, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased to 5, representing 16% of headcount.

  • Jun 22, 2026

    Monthly visitors grew 34% MoM.

PolyActiva Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PolyActiva Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PolyActiva's valuation, stock price, and market status.

Firmographic Details

HeadquartersMelbourne
Employee Range32
Year Founded2010
Last FundingMay 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?